Safety of lacosamide in children with refractory partial epilepsy  by Pasha, Ismail et al.
Saudi Pharmaceutical Journal (2015) 23, 556–561King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESafety of lacosamide in children with
refractory partial epilepsy* Corresponding author at: KLE University’s J N Medical College,
In-charge Child Development Clinic, KLES Prabhakar Kore Hospital,
Belgaum, Karnataka State, India. Tel.: +91 9449818121.
E-mail address: drmaheshkamate@gmail.com (M. Kamate).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2015.01.006
1319-0164 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ismail Pasha a, Mahesh Kamate b,*, D.K. Suresh ca Dept. of Pharmacology, KLE University’s College of Pharmacy, Belgaum, Karnataka State, India
b Dept. of Pediatric Neurology, KLE University’s J N Medical College, KLES Prabhakar Kore Hospital,
Belgaum, Karnataka State, India
c Dept. of Pharmacology, Luqman College of Pharmacy, Jevargi Road, Gulbarga, Karnataka State, IndiaReceived 5 November 2014; accepted 1 January 2015
Available online 24 January 2015KEYWORDS
Behaviour;
Adverse effects;
Refractory partial epilepsy;
Lacosamide;
HyperactivityAbstract Objectives: The study was carried out to investigate the safety of lacosamide on children
with refractory partial epilepsy.Materials &methods:The study was carried out at a tertiary care hos-
pital after obtaining approval from the institutional ethics committee. Patients aged between 5 and
15 years taking oral lacosamide (LCM) tablets that were given orally as an adjunctive anti-epileptic
drug were enrolled for assessing safety, tolerability and its effect on the behavioural life at every visit
of titration, during the treatment period (3 months) and at 2 follow up visits that were done atmonthly
intervals. Adverse events reported by caregiver or by investigator were recorded. Patients/caregivers
also completed a 25 items on Connor’s behavioural rating clinical scale at every visit. Results: Out of
531 screened patients, 79 patients with refractory partial epilepsy were enrolled after they fulﬁlled the
inclusion and exclusion criteria.Mean age of the childrenwas 8.84 ± 3.09 years (5–15 years), ofwhich
53 were males and 26 females. The mean age at onset of seizures in males was 6.46 ± 3.57 and in
females, 6.38 ± 3.39 years. Seventy-six children of 79, completed 3 months of treatment period
showed signiﬁcant (p< 0.001) decrease in the frequency of seizures, signiﬁcant improvement in
behaviour and showed good tolerability. Three (3.79%) patients dropped out of the study due to
hyperactive behaviour, vomiting and lack of seizure control respectively. Conclusions: Lacosamide
is a well-tolerated newer antiepileptic drug that is effective in refractory partial epilepsy paediatric
patients and concurrently improved patient’s behaviour.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is one of the most frequent neurological disorders
affecting 0.5–1% of the population worldwide. In epilepsy
there is an enduring predisposition of the brain to generate
seizures (Verrotti et al., 2012). Despite the introduction of mul-
tiple newer antiepileptic drugs (AEDs) over the past 20 years,
about 30% of patients with epilepsy become refractory to
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(Kwan and Brodie, 2000; Diaz et al., 2002; Perucca, 2007).
Therefore, attempts to identify novel drug therapies that
reduce the seizure frequency and improves patient’s beha-
vioural life are on. Lacosamide is one of the newer AEDs
which promises to be effective and has a better tolerability
proﬁle.
Based on experimental evidence it was suggested that laco-
samide has a novel mechanism of action: increase of the slow
inactivation of the voltage-gated sodium channels (Errington
et al., 2006; Wang et al., 2010; Brandt et al., 2006; Verrotti
et al., 2013). A pharmacokinetic-pharmacodynamics (efﬁcacy)
analysis was performed based on the pooled data from the 3
efﬁcacy trials for partial-onset seizures. Lacosamide exposure
was correlated with the reduction in seizure frequency
(Verrotti et al., 2013). Lacosamide showed favourable
pharmacokinetics properties, has a low potential for drug–
drug interactions and is thus well suited for polytherapy and
probably for use in children (Beyreuther et al., 2007). Few
studies in adults proved that the proportion of patients with
at least a 50% reduction in seizure frequency (50% responder
rate) with lacosamide 400 and 600 mg/day were statistically
signiﬁcant (Ben-Menachem et al., 2007). Though it is not
approved for use in children, it may have an active role in
the management of paediatric epilepsy because focal seizures
are the most common seizure type in children (Berg and
Shinnar, 1999). From the past 3 years, 7 published studies have
reported similar efﬁcacy and safety of lacosamide as an
adjunctive treatment in infants, children and young adults with
refractory epilepsy (Highlights, 2014; Fattore and Perucca,
2011; Halasz et al., 2009; Chung, 2010; Gavatha et al., 2011;
Guilhoto et al., 2011; Heyman et al., 2012; Rastogi and Ng,
2012; Fernandez et al., 2012; Grosso et al., 2014; Kim et al.,
in press). There have been some reports of hyperactivity with
lacosamide in children. We wanted to study the safety of laco-
samide in children with refractory partial epilepsy. It is a part
of our likely upcoming study on effect and tolerability of laco-
samide in children with refractory partial epilepsy.2. Materials and methods
2.1. Patients
In this prospective study, out of 531 screened patients, 79
patients were enrolled after they fulﬁlled the inclusion and
exclusion criteria. Informed written consent was taken from
the parents and approval from the child obtained whereever
applicable.
2.2. Study design
This, open-label study was conducted over a 30 month dura-
tion, after obtaining approval from Institutional Human
Ethics Committee.
2.3. Inclusion and exclusion criteria
Patients were enrolled based on inclusion criteria of age
between 5 and 15 years and those who have had at least
3 month duration of uncontrolled focal epilepsy even afteruse of 1–4 AEDs. One month before enrolment patients were
to have at least 2 seizures. Patients were excluded from the
study if they had an underlying metabolic and systemic disor-
der and if they were diagnosed with pseudo seizures and if they
had a progressive neurological disorder. Patients with history
of noncompliance and use of investigational drug within
1 month prior to the study were also excluded from the study.
Lacosamide was added to a stable regime of baseline AEDs
were administered orally in the form of tablets at a dose of
25 mg twice a day for one week followed by 50 mg twice a
day for the remaining period. During the study period,
patients were asked to report or call principal investigator
(PI) if they developed any complaint or reaction.
2.4. Study assessments
Diagnosis of epileptic seizures and syndromes was based on
Classiﬁcation of Epileptic Seizures (Commission on
Classiﬁcation and Terminology of the International League
against Epilepsy, 2011) (Berg and Ingrid, 2011). After review-
ing the semiology of seizures, electroencephalography (EEG)
and magnetic resonance imaging (MRI) ﬁndings.
At enrolment, after detailed physical examinations, serum
samples were drawn to assess transaminase (SGOT/SGPT)
levels and an ECG was recorded. Later patients entered into
a 3-month maintenance period and two follow up visits of
one month interval. Electrocardiogram (ECG) and transami-
nase levels were estimated at the end of 3 months of mainte-
nance period. No change in the dose of lacosamide was
permitted during the maintenance period.
The efﬁcacy measures were analysed based on change in
seizure frequency per 28 days. Children experiencing P50%
or greater reduction in seizure frequency from baseline to
maintenance period and also patients who were seizure free
were noted.
The assessment of safety and tolerability was performed at
every visit and it consisted of collecting data on adverse events
reported by the patient or their caregiver or those observed by
the investigator. Patients who were unable to tolerate protocol
medication and those experiencing adverse effects were
allowed to discontinue treatment. In our study, we measured
tolerability based on global ﬁve point scale (A score of 5 was
given when there was decrease in side effects; a score of 4 when
there were no new side effects; score of 3 when there was one
new side effect; score of 2 when there were 2–3 side effects and
a score of 1, when there were >3 side effects.).
At the same time, parents or their patients were made to
complete 25 items of Connor’s CBRS clinical index scale. A
high score on an item indicates difﬁculty in that area of the
patient’s life. The total score can range from 10 indicating
good behaviour to 75 indicating low quality behavioural life.
Caretakers were provided with diary cards, which captured
the details of seizures per month, medications taken in the
morning and evening, from the beginning of titration period
till last evaluation.
2.5. Statistical analysis
Tolerability and effect of lacosamide on the children’s beha-
viour outcome measured using SPSS 20.0 for Windows (IBM
Corporation, Armonk, NY, USA) were used for the statistical
Table 2 Demographic data and patient characteristics.
Characteristics Value
Age, year 8.84 ± 3.09
Sex, n (%)
Male (53) 8.93 ± 3.09
Female (26) 8.65 ± 3.31
Follow up duration on lacosamide
Continued 49 (62.02%)
Discontinued after treatment period 27 (35.5%)
Co-administered drugs along with lacosamide (LCM) n (%)
1 38 (48.1%)
2 35 (44.3%)
3 05 (6.3%)
4 00 (0.0%)
5 01 (1.35%)
Onset of seizure
Males 6.46 ± 3.57
Females 6.38 ± 3.39
Duration of seizure
<1 month 20 (25.3%)
1 month–1 year 15 (19.0%) 15 (19.0%)
1–2 year 15 (19.0%)
>3 29 (36.7%)
Co-administered drugs: VPA: valproic acid, CLB: clobazam, CBZ:
carbmazepine, OXC: oxcarbamazepine, LMT: lamotrigine, LEV:
levetiracetam, TPM: topiramate, PHT: phenytoin, ZNS: zonisa-
mide, PB: phenobarbitone, CNZ: clonazepam, NPM: nitrazepam.
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Wilcoxon signed rank test. The response to lacosamide treat-
ment in improving children’s behaviour was analysed using
repeated measure ANOVA. Statistical signiﬁcance was set at
p< 0.05.
3. Results
3.1. Demographics data and patient characteristics
Out of 531 screened patients, 79 patients were enrolled after
they fulﬁlled the inclusion and exclusion criteria. Seventy-six
(96.2%) patients completed 3 months of maintenance period.
Three patients discontinued due to adverse events. The disposi-
tion of patients is summarized in Table 1.
The clinical characteristics of 79 patients with refractory
partial epilepsy are presented in Table 2. In this study, 53
(69.7%) children were males and 23 (30.2%) were females with
a mean age of 8.84 ± 3.09 years (age range 5–15 years). Mean
age at seizure onset in males was 6.46 ± 3.57 years and in
female, 6.38 ± 3.39 years. Out of 76, 49 (62.02%) children
continued lacosamide even after the completion of treatment
period while 27 (35.5%) children stopped it after treatment
period.
Out of 79 enrolled patients, 3 patients were dropped from
the study. The behavioural life of the remaining 76 patients
was assessed using 25 item questionnaire that was ﬁlled by par-
ents/care takers/attenders. Mean total score at baseline was
48.04 ± 10.57; after 3 months of maintenance period, mean
behavioural life was 19.27 ± 08.03 and subsequent follow up
visit was 19.05 ± 05.29 as shown in Fig. 1. Thus scores
improved signiﬁcantly with treatment (ANOVA test with
P< 0.001). Thus behavioural scores remained relatively
constant from baseline to treatment period to all subsequent
follow up visits.
3.2. Efﬁcacy
At the end of the study (EOS), 76 patients entered the mainte-
nance period with a mean reduction in seizure frequency per
28 days from 13.35 ± 24.12 at baseline to 4.53 ± 13.23 at
the EOS (Wilcoxon signed ranked test p< 0.001). At the
end of the follow up period, mean reduction in seizure was
3.9 ± 11.81 as shown in Table 3.
3.3. Adverse effects
All enrolled patients were included in the safety analysis, which
included study of adverse events, laboratory test results andTable 1 Patient disposition.
Study details Value
No. of patients enrolled 79
No. of patients completed 76 (96.2%)
No of patients completed 3 months of
treatment duration
46 (58.2%)
No. of patients continued even after
treatment period
30 (37.9%)
No. of patients discontinued the study 03 (3.79%)vital signs. Out of 79 patients, 40 (50.63%) experienced side
effects.
The common adverse events were hyperactivity, ataxia,
drowsiness, insomnia, weight gain, nausea, abdominal discom-
fort, giddiness, headache, and vomiting as shown in Fig. 2.
Most of the reported side effects were mild to moderate in
intensity and did not need discontinuation of treatment.
Overall results of clinical laboratory tests as well as periodic
physical examinations, neurological examinations and assess-
ments of vital signs did not reveal any changes with lacosamide
treatment.
Lacosamide was withdrawn in three patients (3.79%).
Reasons for discontinuation were unsatisfactory seizure con-
trol (one patient) and adverse events during the titration and
treatment period (one patient with aggressive behaviour and
one with vomiting).
4. Discussion
This prospective, open label treatment study demonstrates that
adjunctive therapy with oral lacosamide in children with
uncontrolled epilepsy, not only reduces seizure frequency with
better tolerability proﬁle, there is improvement in children’s
behaviour and it causes fewer side effects. The study conﬁrms
the clinical efﬁcacy and tolerability of lacosamide in refractory
epilepsy in children and validates ﬁndings from previous
studies.
In a multicentre prospective study by Verrotti et al. that
compared lacosamide in paediatrics and adults, a total of
118 patients (59 group A, 59 group B) with uncontrolled
Figure 1 LCM study: connors comprehensive behaviour rating scale.
Table 3 Diseases and drug characteristics.
Clinical ﬁndings Values
Males Females
Seizure type
Temporal lobe epilepsy 3 (5.8%) 1 (3.84%)
Frontal lobe epilepsy 13 (25.0%) 7 (26.6%)
Occipital lobe epilepsy 24 (44.2%) 6 (23.0%)
Centrotemporal epilepsy 01 (1.9%) 3 (11.5%)
Multifocal 06 (11.5%) 9 (34.5%)
others 06 (11.5%) 0 (0.0%)
Aetiology classiﬁcation:
Idiopathic/genetic 16 (30.8%) 03 (11.5%)
Structural/metabolic 32 (61.5%) 18 (69.1%)
Cryptogenic/unknown 05 (9.6%) 05 (19.0%)
Retention of lacosamide (months)
66 02 (2.5%)
7–12 20 (25.3%)
13–18 14 (17.7%)
19–24 08 (10.1%)
>24 05 (6.3%)
Discontinued after treatment period 30 (38%)
Connors comprehensive behaviour rating scale
Baseline  mean ± SD 48.04 ± 10.57
End of the study  mean ± SD* 19.27 ± 08.03
Follow up* 19.05 ± 05.29
Seizure frequency per 28 days:
Mean ± SD  baseline 13.3 ± 24.11
End of the study seizure frequency:
Mean ± SD 4.53 ± 13.22
% Reduction (p< 0.001)# 59.9 ± 99.9
# p< 0.001, showed signiﬁcant difference using Wilcoxon signed
ranks test.
* P< 0.001, showed signiﬁcant difference using ANOVA test.
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uation, 118 treated patients and 56 subjects (47.4% group A;
47.4% group B; p= 0.8537) experienced at least 50% reduc-
tion in seizure frequency respectively (Verrotti et al., 2013).In randomized controlled trials conducted in adults, lacosa-
mide has been shown to be an effective and safe AED in treat-
ing refractory seizures, with 30–40% of patients achieving a
P50% reduction in seizure frequency at doses of 400–
600 mg/day (Fattore and Perucca, 2011; Halasz et al., 2009;
Chung, 2010; Berg and Ingrid, 2011; Chung et al., 2010).
In the last 3 years, 7 published studies have reported similar
efﬁcacy and safety of lacosamide in infants, children and
young adults with refractory epilepsy that had shown greater
reduction in seizure frequency and few children with seizure
free status (Gavatha et al., 2011; Guilhoto et al., 2011;
Heyman et al., 2012; Rastogi and Ng, 2012; Fernandez
et al., 2012; Grosso et al., 2014; Kim et al., in press).
Lacosamide has been reported to be a well-tolerated and
relatively safe drug (Buck and Goodkin, 2012). Mild adverse
reactions, such as dizziness, headache, diplopia, nausea and
somnolence, drowsiness, dizziness have been observed in pae-
diatric case reports and case series (Guilhoto et al., 2011;
Heyman et al., 2012; Fernandez et al., 2012; Buck and
Goodkin, 2012). The most common adverse event observed
in our study (50.63%) was almost congruent with those
reported by Gavatha et al., 2011 Adverse effects seen with
lacosamide in adults are dose-related (Buck and Goodkin,
2012) and same was seen in paediatrics. Many of them are
reversible upon discontinuation or dose reduction.
The effect of lacosamide on behaviour in 76 patients was
measured using mean scores. The behavioural scores improved
signiﬁcantly with treatment (ANOVA test with P< 0.001)
using Conner’s Comprehensive Behavior Rating Scales
(Conners, 2007). The scores remained relatively constant from
baseline to treatment period to all subsequent follow up visits.
The possible reasons for a favourable effect of lacosamide on
behavioural scores could be attributed to improved adherence
of children to twice-daily dose of LCM leading to better sei-
zure control and that in turn helped to sustain behavioural
improvements.
In our study population, lacosamide showed greater efﬁ-
cacy and was well tolerated with no relationship between dose
and adverse effects development. Most adverse effects seen
with lacosamide in adults are dose-related and are reversible
Figure 2 LCM study – adverse effect.
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One of the literature stated that patient who received the high-
est lacosamide dose (20 mg/kg/day) did not experience any
adverse effects (Buck and Goodkin, 2012; Vishwanath and
Miller, 2012). Plasma drug levels were not determined in our
study. The literature suggests that adverse effects associated
with lacosamide therapy are generally mild-to-moderate in
severity.
Lacosamide was discontinued in one patient (1.26%)
because of severe hyperactivity, aggression and inattention
for one week after starting the drug. These symptoms persisted
for one month till the drug was continued and the behavioural
symptoms reverted back to normal status after the drug was
stopped (Ismail et al., 2014a,b). Two (2.53%) others withdrew
from study due to vomiting and instability in seizure control
respectively.
5. Conclusions
In conclusion, lacosamide is one of the newest additions to the
AED category and represents a possible option, currently
available for refractory partial epilepsy. To the best of our
knowledge, this is the ﬁrst prospective study in a large sample
of children (>55 subjects). Results from our prospective, open
label, hospital based study conﬁrm the usefulness of LCM for
adjuvant treatment in patients with refractory partial epilepsy.
Lacosamide showed favourable safety, tolerability proﬁle and
improved behavioural life scores with no increase in seizure
frequency. A few more multi-centre randomized controlled tri-
als are required to validate our study results.
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